

Form 51-102F3
Material Change Report

1. Name and Address of Company

Entheon Biomedical Corp.
Suite 720 - 999 W Broadway Street
Vancouver, BC
V5Z 1K5
(the "Company")

2. Dates of Material Change(s)

April 18, 2024

3. News Release(s)

News release was issued on April 18, 2024 and disseminated via Stockwatch pursuant to section 7.1 of National Instrument 51-102.

4. Summaries of Material Changes

The Company is pleased to announce that, further to its news release dated May 11, 2024, it has closed a non-brokered private placement for total gross proceeds of \$147,500 (the "Placement"). The Company has allotted and issued 2,950,000 units (the "Units") at a price of \$0.05 per Unit.

5. Full Description of Material Changes

News Release dated April 18, 2024– See Schedule "A".

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

7. Omitted Information

No information has been omitted.

8. Executive Officer

Mr. Timothy Ko, President, CEO and Director of the Company, is knowledgeable about the material change contained herein and may be reached at (604) 562-3932.

9. Date of Report

This report is dated April 19, 2024

SCHEDULE "A"
to the Material Change Report dated April 19, 2024

Entheon Biomedical Announces Closing of Private Placement Financing

VANCOUVER, BC, April 18, 2024 – Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("**Entheon**" or the "**Company**") is pleased to announce that, further to its news release dated May 11, 2024, it has closed a non-brokered private placement for total gross proceeds of \$147,500 (the "**Placement**").

The Company has allotted and issued 2,950,000 units (the "**Units**") at a price of \$0.05 per Unit. Each unit consists of one common share of the Company and one transferable share purchase warrant, each warrant entitling the holder to acquire one additional common share at an exercise price of \$0.10 for a period of 60 months from the closing date.

The Company will use the proceeds from the Placement towards general working capital. All securities issued under the Placement are subject to a hold period of four months and one day expiring on August 19, 2024.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

<https://entheonbiomedical.com>